3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1H-pyrazol-4-yl)pyridin-2-amine | 756509-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1H-pyrazol-4-yl)pyridin-2-amine
• 英文别名: 3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1H-pyrazol-4-yl)-pyridin-2-ylamine；3-(1-(2,6-dichloro-3-fluoro-phenyl)ethoxy)-5-(1H-pyrazol-4-yl)-pyridin-2-amine；3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1H-pyrazol-4-yl)pyridin-2-amine
• CAS: 756509-08-7
• 化学式: C₁₆H₁₃Cl₂FN₄O
• 分子量: 367.21
• InChiKey: VTOQQRYPFKINSB-UHFFFAOYSA-N

物化性质

• 沸点：
  545.1±50.0 °C(Predicted)
• 密度：
  1.458±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1H-pyrazol-4-yl)pyridin-2-amine 、 3,4-二甲氧基苄醇 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成
  参考文献：
  名称：

  WO2008/53157

  摘要：

  公开号：
• 作为产物：
  描述：

  2,6-二氯-3-氟苯乙酮 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-碘代丁二酰亚胺 、 lithium aluminium tetrahydride 、 铁粉 、 caesium carbonate 、 溶剂黄146 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 水 、 溶剂黄146 、 甲苯 、 乙腈 为溶剂， 反应 24.5h， 生成 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1H-pyrazol-4-yl)pyridin-2-amine
  参考文献：
  名称：

  Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

  摘要：

  Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design. A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3. In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE). Further optimization of the lead series generated the clinical candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.

  DOI：

  10.1021/jm2007613

文献信息

• Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
  申请人：Cui Jean Jingrong

  公开号：US20060046991A1

  公开（公告）日：2006-03-02

  Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了式1的对映纯化合物，以及它们的合成和使用方法。优选化合物是c-Met蛋白激酶的强效抑制剂，并且在治疗异常细胞生长紊乱，如癌症方面具有用处。
• PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Hu Baihua

  公开号：US20120220551A1

  公开（公告）日：2012-08-30

  The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.

  本发明涉及由式(I)表示的化合物，可调节蛋白激酶的活性。该发明还涉及含有式(I)化合物的组合物，以及用于合成和使用此类化合物以预防或治疗ALK或cMet介导的疾病或状况的方法。
• Crizotinib Preparation Method
  申请人：ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD.

  公开号：US20150307476A1

  公开（公告）日：2015-10-29

  The present invention relates to the technical field of medicine and organic synthesis, particularly to a method for preparing crizotinib. The method comprises the compound of formula b and the compound of formula e undergoing Suzuki coupling reaction to produce the compound of formula a which then was subjected to deprotection to afford (±) crizotinib.

  本发明涉及医药和有机合成技术领域，特别是一种制备克唑替尼的方法。该方法包括通过式b化合物和式e化合物进行铃木偶联反应，生成式a化合物，然后对其进行去保护以得到(±)克唑替尼。
• [EN] PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES AMINOHETEROARYLE A SUBSTITUTION PYRAZOLE SERVANT D'INHIBITEURS DE PROTEINE KINASE
  申请人：PFIZER

  公开号：WO2006021881A2

  公开（公告）日：2006-03-02

  Compounds of formula (1) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了化学式（1）的化合物，以及它们的合成和使用方法。优选的化合物是c-Met蛋白激酶的有效抑制剂，并可用于治疗异常细胞生长障碍，如癌症。
• Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
  申请人：Cui Jean Jingrong

  公开号：US20060128724A1

  公开（公告）日：2006-06-15

  Compounds of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了化学式1的化合物，以及它们的合成和使用方法。首选的化合物是c-Met蛋白激酶的强效抑制剂，并且在治疗异常细胞生长障碍，例如癌症方面非常有用。